Please assess the completion status of the following clinical trial:

Trial Title: Safety Study of Human IgM (MORAb-028) to Treat Metastatic Melanoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed AJCC Stage IIIB, IIIC or IV melanoma with injectable metastases (in transit, intradermal, or subcutaneous nodules)~* Tumor accessible to intra-tumoral injections~* Cumulative tumor volume great enough to accept MORAb-028 injections for a given dose level, based on intent to inject at a concentration of 1 mg/cm3~Exclusion Criteria:~* Are candidates for curative surgical excision or lymphadenectomy~* Prior non-surgical treatment within 4 weeks~* Known central nervous system (CNS) tumor involvement or metastases~* Hypersensitivity to MORAb-028

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MORAb 028 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).